Roth Capital analyst Dave King today issued a note in which he reiterated a Buy rating on American Apparel (NYSE:APP) and raised his price …
In a research report released today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Epizyme (NASDAQ:EPZM) with a $52 price target, following the company’s second-quarter financial results and update on …
Acura Pharmaceuticals (ACUR) announced preliminary outcomes from its August 14 meeting with the FDA in which the Agency requests an additional nasal abuse liability study …
In a research note published today, H.C.
In a research report issued Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target, which represents a …
For the first time, Dendreon Corp. (DNDN) acknowledged the magnitude of the risk its 2016 convertible debt has on shareholders.
Intel Corp. (INTC) issued a press release on Wednesday announcing it has signed a definitive agreement to acquire LSI’s Axxia Networking Business and related assets …
In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on shares of Catalyst Pharmaceutical (CPRX) with a $3.50 price target, following the company’s second-quarter results.
In a research report published August 14, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Synthetic Biologics (SYN) with a $6 price target, following the company’s second-quarter results, burning …
In a research note released August 14, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following the company’s second-quarter results. Tekmira ended the quarter …
